What's Happening?
Goldman Sachs has slightly raised the target price for Shanghai Pharmaceuticals (02607.HK) to HKD10.3, reflecting adjustments in net profit forecasts for 2026-2027. The company's 4Q25 revenue was RMB68.5 billion, up 4.4% year-on-year, surpassing Goldman Sachs'
forecast of RMB65.9 billion. Despite this revenue increase, the net profit for the same period was RMB578 million, up 16% year-on-year but below the broker's estimation of RMB1.2 billion. The discrepancy is attributed to increased selling expenses due to the commercialization of innovative drugs, along with investment losses and asset impairments.
Why It's Important?
The adjustment in Shanghai Pharmaceuticals' target price and profit forecasts by Goldman Sachs highlights the challenges faced by the company in balancing revenue growth with profitability. The increased selling expenses and investment losses indicate potential risks in the company's strategy to commercialize innovative drugs. This development may affect investor sentiment and influence stock performance, as stakeholders reassess the company's financial health and strategic direction. The pharmaceutical sector may see shifts in investment patterns as analysts and investors react to these changes.
